Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget’s disease

Monique R Watts, Andris H Ellims and David S Eccleston
Med J Aust 2014; 200 (3): . || doi: 10.5694/mja13.11524
Published online: 17 February 2014

To the Editor: Use of bisphosphonates for fracture prevention is increasing. These agents have potential adverse effects,1 but are not known to cause myocardial injury. We present a case of myopericarditis following administration of intravenous zoledronic acid.

  • 1 Royal Melbourne Hospital, Melbourne, VIC.
  • 2 Alfred Hospital, Melbourne, VIC.


Competing interests:

No relevant disclosures.

  • 1. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009; 84: 632-638.
  • 2. Friedrich MG, Sechtem U, Schultz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.